British Company and Siam Bioscience Launch Cell and Gene Therapy Centre in Thailand

Oct 2025

eXmoor Pharma, a British contract development and manufacturing organization specializing in cell and gene therapies, has entered a strategic partnership with Siam Bioscience, a leading biopharmaceutical company in ASEAN, to establish a regional center for the development and manufacturing of advanced therapies. The new facility, based near Bangkok, aims to accelerate the growth of Thailand’s and Southeast Asia’s cell and gene therapy industry while providing comprehensive support for local innovation and global collaborations.

Cell and gene therapies are advanced medicines that use living cells and genetic material to treat severe and rare diseases, including cancer and genetic disorders. Manufacturing these therapies requires highly controlled and reproducible processes, covering cell harvesting, expansion, gene transduction, and patient infusion. The partnership combines eXmoor’s consultancy and technical expertise with Siam Bioscience’s regional manufacturing capabilities, offering services such as process and analytical development, as well as GMP-compliant clinical and commercial production.

The center will serve as a platform to introduce international therapies into the region, enhancing patient access to globally aligned treatments and supporting sustainable healthcare systems. By providing locally based but internationally standard manufacturing, the collaboration seeks to reduce logistical delays, improve efficiency, and expand equitable access to transformative therapies.

Angela Osborne, Executive Chair of eXmoor Pharma, emphasized the goal of supporting both local breakthroughs and international partnerships, bringing therapies to more patients efficiently. Songpon Deechongkit, CEC at Siam Bioscience, highlighted that the center will facilitate translational research and commercialization of cell and gene therapies in Thailand and neighbouring countries.

Siam Bioscience has over 15 years of experience in biopharmaceutical research, development, manufacturing, and technology transfer, with EU GMP-certified facilities. This partnership marks its expansion into advanced therapeutic modalities, including cell and gene therapies, supporting the broader mission to improve access to innovative healthcare solutions across Thailand, ASEAN, and surrounding regions.

(Source: Pharma Focus Asia)

About Us

Orissa International helps companies that want to develop a market entry strategy for Southeast Asia or implement their business expansion into the region. We have very strong domain knowledge of markets and industry sectors, and a business network of over 15,000 companies that includes distributors, resellers, system integrators and local manufacturers, that we have built through advising and guiding more than 4,000 companies with their market expansion into the ASEAN region over the last 28 years.

Orissa International is headquartered in Singapore, with additional offices in Malaysia, Indonesia, Thailand, Vietnam, and the Philippines.

Our Services